Home -> Law Blog Directory -> Intellectual Property Law Blogs -> Orange Book Blog: At the Intersection of Patent Law and FDA Law
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Intellectual Property Law
: Orange Book Blog: At the Intersection of Patent Law and FDA LawBook Review: Generic Pharmaceutical Patent and FDA Law
By Aaron Barkoff
Shashank Upadhye has written a new text, Generic Pharmaceutical Patent and FDA Law, that anyone reading Orange Book Blog will certainly find useful. Mr. Upadhye is Vice President & Global Head of Intellectual Property for Apotex.
The book provides a nice overview of patent law--especially as applied to pharmaceuticals--and the drug approval process. In addition, it includes detailed chapters on issues that arise from the Hatch-Waxman Act, including Orange Book patent certifications and notice letters, the 30-month stay, 180-day exclusivity and forfeiture, and declaratory judgment. A complete list of the book's chapters appears below.
Generic Pharmaceutical Patent and FDA Law is incredibly current, citing not only cases that were decided this year, but also FDA decisions made this year and even numerous pending cases. The book also excels by offering countless practice tips. It is not simply a legal treatise. Moreover, despite its focus on generic drugs, those who work with brand-name drug companies will also find the book helpful because it describes the issues facing generic drug companies.
Generic Pharmaceutical Patent and FDA Law is published by Thomson/West and is available to purchase from their website. To receive a 10% discount on the book, use promo code 571793 or click here.
Chapter Listing:
- Basics of Patent Law
- Patent Infringement Rules and Procedures
- Foundations of Patent Invalidity
- Inequitable Conduct and Unenforceability
- Equitable Defenses to Patent Infringement
- Basics of Brand Drug Approval Process and Orange Book Listings
- Abbreviated New Drug Application (ANDA) Approval Process
- "Paper NDA" and 505(b)(2) Applications
- Patent Infringement Safe Harbor Exemptions
- Mechanics of Orange Book Patent Certifications and Notice Letters
- The 30-Month Injunction/Stay
- Brand Side Exclusivities
- The 180-Day Exclusivity
- Forfeiture of the 180-Day Exclusivity
- Declaratory Judgment
- Patent Infringement Damages and Remedies
Full post as published by Orange Book Blog: At the Intersection of Patent Law and FDA Law on July 08, 2008 (boomark / email).
Zantac Patent
GlaxoSmithKline and Cypress Pharmaceutical settle patent infringement dispute.
The Princeton Review
$2.6 million settlement reached in patent infringement case.
Soliris Patent
Alexion Pharmaceuticals Inc. agrees to pay the Oklahoma Medical Research Foundation a $10 million patent infringement settlement.
ETHEX Corp
5 Generic Drugs Recalled Due to Risk of Death From Overdose
DRAM Patent
ProMOS Technologies and Mosel Vitelic pay MOSAID Technologies an undisclosed patent infringement settlement.
Generic Versions
Barr Pharmaceuticals to pay $5.9 million settlement for blocking the sale of oral contraceptives.

Launching the Indian Generic Pharmaceutical Patent Academy
Book Review: The Generic Challenge
ACI Maximizing Pharmaceutical Patent Lifecycles Conference
Maximizing Pharmaceutical Patent Life Cycles
Tussle Over Participation In India Compulsory Licence Hearing









